PharmatrophiX, a Menlo Park, CA-based healthcare technology company, raised $5.5m in funding.
The round was led by evergreen fund Dolby Family Ventures, which invested $2m.
The company intends to use the funds to continue their path to human clinical trials.
Led by Frank Longo, M.D., Ph.D., Chairman of the Board and Founder, PharmatrophiX focuses on the development of disease-modifying small molecule drugs targeting mechanisms underlying neurodegenerative and other disorders.
FinSMEs
06/10/2014